Teresa Alonso‐Gordoa

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Enrique Grande, Jaume Capdevila, Daniel Castellano et al. · Annals of Oncology · 2015 · 157 citations · Full text

Medicine, Oncology, Pharmacology +13

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason et al. · Journal of Clinical Oncology · 2021 · 126 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca et al. · Journal of Clinical Oncology · 2019 · 76 citations · Full text

Medicine, Endocrinology, Oncology +14

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Sandip Pravin Patel, Teresa Alonso‐Gordoa, Susana Banerjee et al. · Journal for ImmunoTherapy of Cancer · 2024 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17